Compare CTW & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTW | BDSX |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.2M | 153.3M |
| IPO Year | N/A | 2020 |
| Metric | CTW | BDSX |
|---|---|---|
| Price | $2.24 | $22.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 22.4K | ★ 67.4K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $1.10 | $0.33 |
| 52 Week High | $3.14 | $24.92 |
| Indicator | CTW | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 60.22 |
| Support Level | N/A | $19.00 |
| Resistance Level | N/A | $24.92 |
| Average True Range (ATR) | 0.00 | 1.72 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 0.00 | 65.36 |
CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.